Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Jane H. Buckner, MD

Benaroya Research Institute at Virginia Mason
Seattle, WA, United States

Jane Buckner is the President of the Benaroya Research Institute at Virginia Mason (BRI), Affiliate Professor of Immunology at the University of Washington, and Affiliate Professor of Medicine, Division of Rheumatology also at the University of Washington. Dr. Buckner’s interdisciplinary research combines genetics, immunology and clinical medicine to advance our understanding of the causes of autoimmune diseases. Her research is focused on understanding the mechanisms through which self-tolerance is lost in human autoimmune disease. The diseases studied in the laboratory include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and relapsing polychondritis. The research goal is to expand our understanding of each disease by identifying the common features that cause them. Her research group has approached this question through the study of genetic risk variants associated with autoimmunity, analysis of regulatory and effector adaptive responses in samples from patients with autoimmune disease and targeted analysis of autoreactive CD4 T cells from patients with autoimmunity.

Presentation(s):

  • Antigen Specific Therapy: Is It the Holy Grail for Autoimmunity?

    Monday, November 13, 2023
    12:00 PM – 12:45 PM PT

    Disclosure(s): Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Gentibio: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Intellectual Property/Patents (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); hotspot therapeutics: Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Omeros: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)

  • 1762: Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Gentibio: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Intellectual Property/Patents (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); hotspot therapeutics: Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Omeros: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)

Back to Top